Acute hemolytic reaction by anti-Wra: Case report and review of the hemovigilance database of a tertiary care hospital.


Journal

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
ISSN: 1473-0502
Titre abrégé: Transfus Apher Sci
Pays: England
ID NLM: 101095653

Informations de publication

Date de publication:
Jun 2022
Historique:
received: 30 10 2021
revised: 03 12 2021
accepted: 13 12 2021
pubmed: 1 1 2022
medline: 22 6 2022
entrez: 31 12 2021
Statut: ppublish

Résumé

Wra is the most common LIA in white population. The incidence of Wra antigen in Spanish population has been estimated to be 1 in 785 in blood donors, while anti-Wra was found in 2.7 % and 3.6 % of healthy donors and transfused patients respectively. Severe, even fatal hemolytic transfusion reactions and hemolytic disease of the newborn caused by anti-Wra have been reported. Since the reagent red blood cells used for antibody screening usually lack Wra antigen, the anti-Wra is not detected and hemolytic reaction could occur if transfusion is performed by type and screen approach. We report an acute hemolytic reaction due to anti-Wra in a patient with negative antibody screening. We have also reviewed the records of the hospital hemovigilance database in order to collect the previous hemolytic cases due to anti-Wra. During a 21-year period 461,539 red blood cell units have been transfused to 81,614 patients in our hospital. Alloimmnunization was detected in 3840 patients (0.83 %) and anti-Wra was detected in 22 patients (1/3709), 10 of whom had other alloantibodies, and only in 1 occasion (this case) has been implicated in mild hemolytic acute transfusion reaction. In our experience, the risk of fatal hemolytic reaction due to LIA in hospitals with blood services using the type and screen policy is extremely low.

Identifiants

pubmed: 34969586
pii: S1473-0502(21)00350-5
doi: 10.1016/j.transci.2021.103342
pii:
doi:

Substances chimiques

Isoantibodies 0

Types de publication

Case Reports Journal Article

Langues

eng

Pagination

103342

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Auteurs

Pilar Solves (P)

Blood Bank, Hematology Unit, Hospital Universitari i Politècnic la Fe, Valencia, Spain. Electronic address: solves_pil@gva.es.

Susana Tur (S)

Blood Bank, Hematology Unit, Hospital Universitari i Politècnic la Fe, Valencia, Spain.

Inés Gómez-Seguí (I)

Blood Bank, Hematology Unit, Hospital Universitari i Politècnic la Fe, Valencia, Spain.

María Viel (M)

Blood Bank, Hematology Unit, Hospital Universitari i Politècnic la Fe, Valencia, Spain.

Juan Eiris (J)

Blood Bank, Hematology Unit, Hospital Universitari i Politècnic la Fe, Valencia, Spain.

Yolanda Planells (Y)

Blood Bank, Hematology Unit, Hospital Universitari i Politècnic la Fe, Valencia, Spain.

Raquel Rodríguez (R)

Blood Bank, Hematology Unit, Hospital Universitari i Politècnic la Fe, Valencia, Spain.

Isabel Peñalver (I)

Blood Bank, Hematology Unit, Hospital Universitari i Politècnic la Fe, Valencia, Spain.

Emma Castro (E)

Blood Bank, Hematology Unit, Hospital Universitari i Politècnic la Fe, Valencia, Spain.

Javier de la Rubia (J)

Blood Bank, Hematology Unit, Hospital Universitari i Politècnic la Fe, Valencia, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH